VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China


January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natriuretic peptide) for injection to the National Medical Products Administration (NMPA) for the treatment of achondroplasia (ACH) patients. Phase II new drug clinical trial application has been approved. The ACcomplisH China clinical trial is about to be launched in China, achieving global synchronization with ACcomplisH (a TransCon C-type natriuretic peptide phase II global clinical trial being carried out by Ascendis Pharma).

TransCon CNP inhibits the over-activated fibroblast growth factor receptor 3 (FGFR3) signaling pathway by continuously providing active CNP. Slowly released once a week to help children with ACH rebuild the balance of bone growth, while improving and preventing the complications of ACH. TransCon CNP has obtained orphan drug designation from the US Food and Drug Administration and the European Commission.